SB-269970 Uses, Dosage, Side Effects and more
SB-269970 is an experimental drug developed by GlaxoSmithKline. In the studies performed with this agent, it has been suggested that SB-269970 acts either as a selective antagonist or inverse agonist of the serotonin receptor 7 (5-HT7).
| Trade Name | SB-269970 |
| Generic | SB-269970 |
| Type | |
| Formula | C18H28N2O3S |
| Weight | Average: 352.49 Monoisotopic: 352.182063944 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
